Harmonic Drive Systems (HSYDF) Was Downgraded to a Sell Rating at Jefferies
Hold Rating on Harmonic Drive Systems Amidst Sales Decline and Uncertain Recovery
Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects
Third Harmonic Bio Analyst Ratings
Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20
Buy Rating Justified by Third Harmonic Bio's Promising Drug THB335 and Swift Clinical Advancements
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)
Harmonic Price Target Raised to $20.00/Share From $14.00 by Barclays
Needham Maintains Harmonic(HLIT.US) With Buy Rating, Maintains Target Price $18
Buy Rating Affirmed for Harmonic on Strong Q2 Performance and Market Leadership in VCMTS Software
Harmonic Analyst Ratings
Barclays Keeps Their Buy Rating on Harmonic (HLIT)
Harmonic Analyst Ratings
Third Harmonic Bio Analyst Ratings
What 5 Analyst Ratings Have To Say About Harmonic
Harmonic Analyst Ratings
Third Harmonic Bio Analyst Ratings
Buy Rating Affirmed for Harmonic: Strong Customer Upgrades and Sustainable Growth Outlook
Harmonic Analyst Ratings
Analysts' Top Technology Picks: Lantronix (LTRX), Harmonic (HLIT)